



**HAL**  
open science

## Delta opioid receptors are essential to the antiallodynic action of $B_2$ -mimetics in a model of neuropathic pain

Mélanie Kremer, Salim Megat, Yohann Bohren, Xavier Wurtz, Laurent Nexon, Rhian Alice Ceredig, Stéphane Doridot, Dominique Massotte, Eric Salvat, Ipek Yalcin, et al.

### ► To cite this version:

Mélanie Kremer, Salim Megat, Yohann Bohren, Xavier Wurtz, Laurent Nexon, et al.. Delta opioid receptors are essential to the antiallodynic action of  $B_2$ -mimetics in a model of neuropathic pain. *Molecular Pain*, 2020, 16, pp.174480692091293. 10.1177/1744806920912931 . hal-03001604

**HAL Id: hal-03001604**

**<https://hal.science/hal-03001604>**

Submitted on 30 Nov 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Delta opioid receptors are essential to the antiallodynic action of $\beta$ 2-mimetics in a model of neuropathic pain

Journal:	<i>Molecular Pain</i>
Manuscript ID	MPX-19-0124.R1
Manuscript Type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Kremer, Mélanie; UPR 3212, CNRS Megat, Salim; UPR 3212, CNRS Bohren, Yohann; UPR 3212, CNRS Wurtz, Xavier; UPR 3212, CNRS Nexon, Laurent; UPR 3212, CNRS Ceredig, Alice; UPR 3212, CNRS Doridot, Stéphane; UMS 3415, Chronobiotron Massotte, Dominique; UPR 3212, CNRS Salvat, Eric; UPR 3212, CNRS; Hôpitaux universitaires de Strasbourg, Centre d'Évaluation et de Traitement de la Douleur Yalcin Christmann, Ipek; UPR 3212, CNRS Barrot, Michel; UPR 3212, CNRS
Keywords:	$\beta$ 2-mimetics, terbutaline, formoterol, neuropathic pain, mechanical allodynia, opioid system, $\delta$ -opioid
Abstract:	<p>The adrenergic system, because of its reported implication in pain mechanisms, may be a potential target for chronic pain treatment. We previously demonstrated that <math>\beta</math>2-adrenoceptors (<math>\beta</math>2-ARs) are essential for neuropathic pain treatment by antidepressant drugs, and we showed that agonists of <math>\beta</math>2-ARs, i.e. <math>\beta</math>2-mimetics, had an antiallodynic effect per se following chronic administration. To further explore the downstream mechanism of this action, we studied here the role of the opioid system. We used behavioral, genetic, and pharmacological approaches to test whether opioid receptors were necessary for the antiallodynic action of a short acting (terbutaline) and a long acting (formoterol) <math>\beta</math>2-mimetic. Using the cuff model of neuropathic pain in mice, we showed that chronic treatments with terbutaline (intraperitoneal) or formoterol (orally) alleviated mechanical hypersensitivity. We observed that these <math>\beta</math>2-mimetics remained fully effective in <math>\mu</math>-opioid and in <math>\kappa</math>-opioid receptor deficient mice, but lost their antiallodynic action in <math>\delta</math>-opioid receptor deficient mice, either female or male. Accordingly, we showed that the <math>\delta</math>-opioid receptor antagonist naltrindole induced an acute relapse of allodynia in mice with neuropathic pain chronically treated with the <math>\beta</math>2-mimetics. Such relapse was also observed following administration of the peripheral opioid receptor antagonist naloxone methiodide. These data demonstrate that the antiallodynic effect of long-term <math>\beta</math>2-mimetics in a context of neuropathic pain requires the endogenous opioid system, and more specifically peripheral <math>\delta</math>-opioid receptors.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 **Delta opioid receptors are essential to the antiallodynic action of  $\beta_2$ -mimetics in a model**  
4  
5 **of neuropathic pain**  
6  
7  
8  
9

10 Mélanie Kremer<sup>1</sup>, Salim Megat<sup>1</sup>, Yohann Bohren<sup>1</sup>, Xavier Wurtz<sup>1</sup>, Laurent Nexon<sup>1</sup>, Rhian Alice  
11 Ceredig<sup>1</sup>, Stéphane Doridot<sup>2</sup>, Dominique Massotte<sup>1</sup>, Eric Salvat<sup>1,3</sup>, Ipek Yalcin<sup>1</sup>, Michel Barrot<sup>1,\*</sup>  
12  
13  
14

15  
16 <sup>1</sup> *Centre National de la Recherche Scientifique, Université de Strasbourg, Institut des Neurosciences*  
17 *Cellulaires et Intégratives, F-67000 Strasbourg, France*  
18

19  
20 <sup>2</sup> *Centre National de la Recherche Scientifique, Université de Strasbourg, Chronobiotron, F-67000*  
21 *Strasbourg, France*  
22

23  
24 <sup>3</sup> *Hôpitaux Universitaires de Strasbourg, Centre d'Evaluation et de Traitement de la Douleur, F-67000*  
25 *Strasbourg, France*  
26  
27

28  
29  
30  
31 \* **Corresponding author.** Institut des Neurosciences Cellulaires et Intégratives, 8 allée du Général  
32 Rouvillois, F-67000 Strasbourg, France.  
33

34  
35 *E-mail address:* [mbarrot@inci-cnrs.unistra.fr](mailto:mbarrot@inci-cnrs.unistra.fr) (M. Barrot).  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

The adrenergic system, because of its reported implication in pain mechanisms, may be a potential target for chronic pain treatment. We previously demonstrated that  $\beta_2$ -adrenoceptors ( $\beta_2$ -ARs) are essential for neuropathic pain treatment by antidepressant drugs, and we showed that agonists of  $\beta_2$ -ARs, *i.e.*  $\beta_2$ -mimetics, had an antiallodynic effect *per se* following chronic administration. To further explore the downstream mechanism of this action, we studied here the role of the opioid system. We used behavioral, genetic, and pharmacological approaches to test whether opioid receptors were necessary for the antiallodynic action of a short acting (terbutaline) and a long acting (formoterol)  $\beta_2$ -mimetic. Using the cuff model of neuropathic pain in mice, we showed that chronic treatments with terbutaline (intraperitoneal) or formoterol (orally) alleviated mechanical hypersensitivity. We observed that these  $\beta_2$ -mimetics remained fully effective in  $\mu$ -opioid and in  $\kappa$ -opioid receptor deficient mice, but lost their antiallodynic action in  $\delta$ -opioid receptor deficient mice, either female or male. Accordingly, we showed that the  $\delta$ -opioid receptor antagonist naltrindole induced an acute relapse of allodynia in mice with neuropathic pain chronically treated with the  $\beta_2$ -mimetics. Such relapse was also observed following administration of the peripheral opioid receptor antagonist naloxone methiodide. These data demonstrate that the antiallodynic effect of long-term  $\beta_2$ -mimetics in a context of neuropathic pain requires the endogenous opioid system, and more specifically peripheral  $\delta$ -opioid receptors.

**Keywords:**  $\beta_2$ -mimetics, terbutaline, formoterol, neuropathic pain, mechanical allodynia, opioid system,  $\delta$ -opioid

**Abbreviations:** AUC, area under the curve;  $\beta_2$ -ARs,  $\beta_2$  adrenoceptors; COPD, chronic obstructive pulmonary disease; DOP, delta opioid; *i.p.*, intraperitoneal; KOP, kappa opioid; MOP, mu opioid; PWT, paw withdrawal threshold; SSNRIs, selective serotonin-noradrenaline reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressant.

## Background

Antidepressant drugs including tricyclic antidepressants (TCAs) and selective serotonin-noradrenaline reuptake inhibitors (SSNRIs) are among the first-line treatments of neuropathic pain.<sup>1-4</sup> These drugs mainly act by blocking the transporters of noradrenaline and serotonin. The critical role of the noradrenergic component in neuropathic pain relief was first suggested based on the poor clinical effectiveness of selective serotonin reuptake inhibitors (SSRIs).<sup>1-3, 5</sup> The lack of SSRIs action can also be observed preclinically in rodent models of neuropathic pain.<sup>4, 6</sup> This raised the question of the potential role of the adrenoceptor(s), downstream of noradrenaline, in the action of the antidepressant drugs. We previously showed, by using a peripheral nerve injury model,<sup>7</sup> that the antiallodynic effect of chronic antidepressant drugs is mediated by  $\beta_2$  adrenoceptors ( $\beta_2$ -ARs),<sup>8-11</sup> but not by  $\alpha_2$ , nor  $\beta_1$  or  $\beta_3$ -ARs. Following these findings, it has been suggested in animals that  $\beta_2$ -ARs agonists could be beneficial in peripheral neuropathic pain conditions.<sup>12, 13</sup> These data were further supported by some clinical observations, showing in a case report that a  $\beta_2$ -mimetic induced significant relief in 6 patients with neuropathic pain,<sup>14</sup> and in a retrospective epidemiologic study that the relative incidence of post-thoracotomy neuropathic pain was 5-fold lower for patients with a chronic  $\beta_2$ -mimetic treatment.<sup>15</sup>

Interestingly, the antidepressant drug mechanism leading to relief of mechanical hypersensitivity after chronic treatment is also delta-opioid (DOP) receptor dependent.<sup>9, 16-19</sup>

The opioid system plays a leading role in inhibitory controls of pain.<sup>20</sup> It is involved in the direct action of analgesics targeting mu-opioid (MOP) receptors<sup>21</sup> such as morphine, but also in the indirect recruitment of opioid receptors in the action of antidepressant drugs against neuropathic pain.<sup>16, 22, 23</sup> In a similar way to antidepressant drugs, it has been suggested that the effect of  $\beta_2$ -mimetics on neuropathic mechanical allodynia may also involve the endogenous opioid system. Indeed, an acute administration of naltrindole, a DOP receptor antagonist, temporarily suppressed the benefit of chronic treatment with the **very long-acting**  $\beta_2$ -mimetic clenbuterol in a model of sciatic nerve compression,<sup>12</sup> and the effect of the  $\beta_2$ -mimetic terbutaline in a model of diabetic neuropathy.<sup>24</sup> These first data suggested that DOP receptors would be necessary for the therapeutic effect of  $\beta_2$ -mimetics on neuropathic pain, **but still required to be genetically confirmed as well as to test the role of the other opioid receptors**. Based on their half-life,  $\beta_2$ -mimetics can be classified as short-acting  $\beta_2$ -mimetics, such as terbutaline, salbutamol,

1  
2  
3 fenoterol and pirbuterol, which are prescribed for the curative treatment of asthma attacks and chronic  
4 obstructive pulmonary disease (COPD) or the threat of preterm labor; or as long-acting  $\beta_2$ -mimetics,  
5 such as formoterol and salmeterol, which are used as bronchodilators to help controlling and preventing  
6 COPD symptoms. Using transgenic and pharmacological approaches, we evaluated here the role of the  
7 three opioid receptors in the antiallodynic action of two  $\beta_2$ -mimetics, one with a short half-life,  
8 terbutaline (5-6h), and the other with a long half-life, formoterol (12h).<sup>25</sup>

9  
10  
11 In the present study, independently of their half-life, both chronic terbutaline and formoterol  
12 reversed mechanical hypersensitivity in our model of neuropathic pain. Using genetic and  
13 pharmacological approaches, we also showed that DOP receptors, but neither MOP nor kappa-opioid  
14 (KOP) receptors, are necessary for this action of  $\beta_2$ -mimetics.

## 25 26 27 28 **Methods**

### 29 *Animals*

30  
31 Experiments were performed using C57BL/6J mice (Charles River, L'Arbresle, France) between 8 and  
32 10 weeks-old at the time of surgery and in mice deficient for MOP, DOP or KOP receptors or  $\beta_2$ -ARs  
33 and their littermate controls. The generation of mice lacking MOP, DOP or KOP receptors, or  $\beta_2$ -ARs  
34 has been previously described.<sup>26-29</sup> Heterozygote mice were bred in our animal facilities and genotyping  
35 of the litters was done upon weaning. Experiments using transgenic mice were conducted on adult male  
36 and female wild type and knockout littermate mice (for formoterol experiments, to refine the use of  
37 animals and test gender aspects) or on male only (for terbutaline experiments), weighing 20-30 g. When  
38 we used male and female, each experimental group contained the same number of males and females.  
39 As the wild type animals have the same background and the same behavior, they were pooled to form  
40 the control groups. For other experiments with C57BL/6J mice, we used males only. Mice were group-  
41 housed two to five per cage and kept under a 12 hour light/dark cycle with food and water *ad libitum*. A  
42 total of 40 C57BL/6J mice, 44 MOP, 43 DOP, 44 KOP and 24  $\beta_2$ -AR-related mice were used for the  
43 experiments. Experiments were performed in agreement with European guidelines (EU 2010/63) and

1  
2  
3 under protocols approved by the "Comité d'Ethique en Matière d'Expérimentation Animale de  
4 Strasbourg" (CREMEAS, CEEA35). At the end of the experiments, mice were killed by cervical  
5 dislocation according to institutional ethical guidelines. The animal facilities Chronobiotron UMS3415  
6 are registered for animal experimentation under the Animal House Agreement A67-2018-38.  
7  
8  
9

### 10 11 12 13 *Model of neuropathic pain*

14  
15 Neuropathic pain was induced by cuffing the main branch of the right sciatic nerve.<sup>7, 30</sup> Surgeries were  
16 performed under ketamine (68 mg/kg) / xylazine (10 mg/kg) intraperitoneal (i.p.) anesthesia (Centravet,  
17 Tadden, France). The common branch of the right sciatic nerve was exposed and a cuff of PE-20  
18 polyethylene tubing (Harvard Apparatus, Les Ulis, France) of standardized length (2 mm) was  
19 unilaterally inserted around it (Cuff group). The shaved skin was closed using suture. Sham-operated  
20 mice underwent the same surgical procedure without implantation of the cuff (Sham group). All  
21 treatments started between two and three weeks after the surgery.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 *Measure of mechanical allodynia*

34  
35 Mechanical allodynia was tested using von Frey hairs and results were expressed in grams. Tests were  
36 done during the morning, starting at least 2 hours after lights on. Mice were placed in clear Plexiglas  
37 boxes (7 cm x 9 cm x 7 cm) on an elevated mesh screen. Calibrated von Frey filaments (Bioseb,  
38 Vitrolles, France) were applied to the plantar surface of each hindpaw until they just bent, in a series of  
39 ascending forces up to the mechanical threshold. Filaments were tested five times per paw and the paw  
40 withdrawal threshold (PWT) was defined as the lower of two consecutive filaments for which three or  
41 more withdrawals out of the five trials were observed.<sup>30, 31</sup> The person who conducted the tests was  
42 blinded to the treatments.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 *Treatment procedures*

55  
56 The terbutaline treatment began fifteen days after the neuropathy was induced, and it was maintained at  
57 least three weeks. During the treatment, mice received two intraperitoneal injections *per* day (morning  
58  
59  
60



1  
2  
3 and evening) of terbutaline hemisulfate (0.5 mg/kg, 5 mL/kg, Sigma-Aldrich, St. Quentin Fallavier).  
4  
5 The dose was chosen based on a previous dose-response experiment<sup>13</sup>. The drug was dissolved in 0.9  
6  
7 % NaCl solution that was also used for control injections. The injection of naltrindole (5 mg/kg,  
8  
9 subcutaneous, Sigma-Aldrich, St. Quentin Fallavier), a DOP receptors antagonist, was done 36 days  
10  
11 after surgery, *i.e.*, after 21 days of terbutaline treatment, in wild-type, MOP and KOP receptors-deficient  
12  
13 mice. The injection of naloxone methiodide (5 mg/kg, subcutaneous, Sigma-Aldrich, St. Quentin  
14  
15 Fallavier), an opioid receptor antagonist that does not cross the blood-brain barrier, was done following  
16  
17 the same procedure as for naltrindole, but in C57BL/6J mice. In order to evaluate the mechanical  
18  
19 thresholds for nociceptive response, mice were submitted to von Frey tests before and 30 min after the  
20  
21 antagonist injection.  
22  
23

24 Formoterol (Biotrend Chemicals AG, Zürich, Switzerland) was delivered *per os* through the  
25  
26 drinking water with *ad libitum* access as sole source of fluid. The drug was dissolved in water with  
27  
28 0.02% saccharin to increase palatability and control mice received a solution of 0.02% saccharin in  
29  
30 water (vehicle solution). To assess the daily dose of  $\beta_2$ -mimetic that was actually received by the animals  
31  
32 (in  $\mu\text{g}/\text{kg}/\text{day}$ ), the bottles containing the treatment were regularly weighed and we calculated the ratio  
33  
34 between the intake amount of formoterol *per cage* and the weight of the animals. A first set of  
35  
36 experiments (Figure 3) included mice treated with oral formoterol at concentrations 0.5, 0.1, 0.05 or  
37  
38 0.001  $\mu\text{g}/\text{mL}$  and their controls, and Sham mice that received the highest dose of formoterol (0.5  $\mu\text{g}/\text{mL}$ )  
39  
40 to test whether it had an analgesic effect *per se* ( $n = 5$  in each group). Considering the volume of solution  
41  
42 drunk by the mice *per 24 h* (between 3.5 and 5 mL *per mouse*), the 0.5  $\mu\text{g}/\text{mL}$  solution was equivalent  
43  
44 to  $7.27 \pm 0.48 \mu\text{g}/\text{kg}/\text{day}$ , the 0.1  $\mu\text{g}/\text{mL}$  solution was equivalent to  $1.78 \pm 0.10 \mu\text{g}/\text{kg}/\text{day}$ , the 0.05  $\mu\text{g}/\text{mL}$   
45  
46 solution was equivalent to  $0.98 \pm 0.05 \mu\text{g}/\text{kg}/\text{day}$  and the 0.001  $\mu\text{g}/\text{mL}$  solution was equivalent to  
47  
48  $0.2 \pm 0.01 \mu\text{g}/\text{kg}/\text{day}$  (Figure 3(c)).  
49  
50

51 Mice lacking MOP, DOP or KOP receptors received formoterol treatment (0.5  $\mu\text{g}/\text{mL}$ ), in the  
52  
53 drinking water, following the same protocol. Data were pooled from four independent experiments, due  
54  
55 to the non-regular production of mouse breeding. Four additional sets of mice were also used to  
56  
57 pharmacologically assess the role of opioid receptors. Each set was composed of three groups, a sham  
58  
59 and a cuff group treated with the oral vehicle, and a cuff group treated with formoterol (0.5  $\mu\text{g}/\text{mL}$ ).  
60

1  
2  
3 After three weeks of oral treatment, mice received a subcutaneous injection of the MOP receptor  
4 antagonist naloxonazine (Sigma-Aldrich, St. Quentin Fallavier, France, 30 mg/kg) or the DOR receptor  
5 antagonist naltrindole (5 mg/kg) or a saline solution (0.9 % NaCl). All drugs were dissolved in NaCl  
6 0.9%. In order to evaluate the mechanical threshold, mice were submitted to von Frey testing before, 30  
7 min and 1h after the antagonist injection.  
8  
9  
10  
11  
12  
13  
14

### 15 **Data and statistical analysis**

16 Data are expressed as mean  $\pm$  SEM. In figures 1(c) and 3(b), cumulated paw withdrawal thresholds  
17 during treatments were quantified as the area-under-the-curve (AUC) above the pre-treatment value,  
18 calculated by the trapezoidal method.<sup>32</sup> Statistical analyses were performed with STATISTICA 10  
19 (Statsoft, Tulsa, OK, USA) using multifactor analysis of variance (ANOVA). The surgery procedure  
20 (Sham or Cuff) and the treatments were taken as between-group factors. When needed, the time of  
21 measurement (either time course or preinjection vs. postinjection data) was taken as a within-subject  
22 factor. The Duncan test was used for post hoc comparisons. The significance level was set at  $p < 0.05$ .  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

## 37 **Results**

### 38 *Terbutaline treatment in opioid receptor deficient mice*

39  
40  
41 Cuff-implantation induced an ipsilateral mechanical hypersensitivity in wild-type mice, as previously  
42 described<sup>7, 16-18, 30</sup> (Figure 1(a);  $F_{7,231} = 10.25$ ,  $p < 0.001$ ; detailed statistics for all results are given in  
43 Table 1 in Supplemental Material). As previously showed<sup>9, 16-19</sup>, this induction and maintenance of  
44 mechanical hypersensitivity was also similar along the experiment between wild-type, MOP<sup>-/-</sup>, DOP<sup>-/-</sup>  
45 and KOP<sup>-/-</sup> mice (Figure 1(b)) (even though enhanced allodynia between DOP<sup>-/-</sup> and their wild-type  
46 controls has been reported by others in the partial ligation model).<sup>33</sup> Two weeks after Cuff insertion, we  
47 started the treatments with terbutaline (0.5 mg/kg) or the control saline solution (0.9 % NaCl), twice a  
48 day. Terbutaline treatment alleviated the cuff-induced allodynia in wild-type mice after about 13 days  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 of treatment (Figure 1(a)). The same antiallodynic effect was also present in MOP (Figure 1(c);  $F_{3,23} =$   
4  $23.82, p < 0.001$ ) and KOP receptor-deficient mice (Figure 1(c);  $F_{3,23} = 23.82, p < 0.001$ ), while the  
5 terbutaline treatment was ineffective in DOP receptor-deficient mice (Figure 1(c);  $F_{3,23} = 23.82, p <$   
6  $0.001$ ).

7  
8  
9  
10  
11 To confirm this critical role of DOP receptors, we then tested the consequences of an acute  
12 injection of naltrindole in the wild-type, MOP and KOP receptor-deficient mice of the above experiment.  
13 After 3 weeks of treatment with terbutaline or saline, an acute injection of naltrindole induced a relapse  
14 of mechanical hypersensitivity in these mice (Figure 2(a); WT:  $F_{1,33} = 18.83, p < 0.001$ ; MOP<sup>-/-</sup>:  $F_{1,21} =$   
15  $21.61, p < 0.001$ ; KOP<sup>-/-</sup>:  $F_{1,20} = 5.05, p < 0.01$ ). We also controlled that naltrindole *per se* had no effect  
16 in mice with Sham surgery, or in neuropathic mice treated with saline.

#### 26 *Peripherals opioid receptors are involved in terbutaline antiallodynic effect*

27  
28 The acute injection of naloxone methiodide (5 mg/kg), an opioid receptor antagonist that does not cross  
29 the blood-brain barrier, induced an acute relapse of allodynia in Cuff-implanted mice chronically treated  
30 with terbutaline (Figure 2(b);  $F_{1,20} = 10.9, p < 0.01$ ). The same dose of naloxone methiodide had no  
31 effect in mice with Sham surgery treated with saline.

#### 39 *Antiallodynic action of chronic oral formoterol: dose response*

40  
41 For treatment with the long-acting  $\beta_2$ -mimetic formoterol, we chose to use chronic oral administration,  
42 which first required determining the appropriate dose (Figure 3). Cuff implantation induced an ipsilateral  
43 mechanical allodynia (Figure 3(a);  $F_{11,242} = 5.8, p < 0.001$ ). We did not observe any change in the  
44 nociceptive threshold on the left paw or in the Sham group. Nineteen days after surgery, we started  
45 treatments with formoterol (0.001, 0.05, 0.1 or 0.5  $\mu\text{g/mL}$ ) or with saccharin vehicle solution (0.02%  
46 saccharin). Chronic formoterol treatment at doses 0.05, 0.1 and 0.5  $\mu\text{g/mL}$  alleviated the cuff-induced  
47 allodynia after nineteen days, fifteen days and thirteen days of treatment respectively (Figure 3(a);  $F_{11,242}$   
48  $= 5.8, p < 0.001$ ). The 0.001  $\mu\text{g/mL}$  dose of formoterol had no significant effect; and treatments at  
49 different doses did not affect the contralateral nociceptive thresholds (Left Paw, Figure 3(a)). The area  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 under the curve (AUC) for the treatment period is presented in Figure 3(b). The drinking bottles were  
4 regularly weighed during the experiment. Considering the volume of solution drunk by the mice *per* 24  
5 h, the 0.001 µg/mL solution was equivalent to 0.2±0.01 µg/kg/day, the 0.05 µg/mL solution was  
6 equivalent to 0.98±0.05 µg/kg/day, the 0.1 µg/mL solution was equivalent to 1.78±0.10 µg/kg/day and  
7 the 0.5 µg/mL solution was equivalent to 7.27±0.48 µg/kg/day (Figure 3(c)). These amounts were in  
8 fact mostly taken over the 12 h night period, period during which mice usually drink.  
9  
10  
11  
12  
13  
14

15 To test whether formoterol had an analgesic effect *per se*, we tested the higher dose (0.5 µg/mL)  
16 in Sham control mice. This chronic oral treatment did not affect mechanical thresholds of the Sham  
17 group (Figure 3(d)).  
18  
19  
20  
21  
22  
23

#### 24 *Chronic oral formoterol treatment in opioid and β<sub>2</sub>-adrenergic receptor deficient mice*

25 As previously observed,<sup>9, 34</sup> mechanical sensitivity thresholds of female mice were significantly lower  
26 than in males (baseline thresholds: 3.4 g ± 0.7 for females, 4.9 g ± 0.9 for males,  $t_{11} = 4.18$ ,  $p < 0.005$ ).  
27 Both male and female mice developed mechanical allodynia after surgery, and formoterol treatment  
28 suppressed the cuff-induced allodynia in both sexes (Figure 4(a); Female mice:  $F_{10,90} = 2.2$ ,  $p < 0.01$ ;  
29 Male mice:  $F_{10,90} = 5.4$ ,  $p < 0.001$ ). Groups including the same number of male and female mice were  
30 pooled for data presentation (Figure 4(b), (c) and (d)).  
31  
32  
33  
34  
35  
36  
37  
38

39 MOP-, DOP-, KOP-receptors or β<sub>2</sub>-AR deficient mice displayed the same baseline for  
40 mechanical sensitivity and cuff-induced mechanical hypersensitivity as their wild-type littermates, as  
41 previously observed.<sup>9-11, 16-18</sup> Formoterol treatment alleviated cuff-induced allodynia in wild-type mice  
42 (Figure 4(b);  $F_{10,210} = 5.6$ ,  $p < 0.001$ ). The same antiallodynic effect was also present in MOP (Figure  
43 4(c);  $F_{10,150} = 5.5$ ,  $p < 0.001$ ) and KOP receptor-deficient mice (Figure 4(c);  $F_{10,150} = 4.1$ ,  $p < 0.001$ ),  
44 while formoterol treatment was ineffective in DOP receptor-deficient mice (Figure 4(c);  $F_{10,150} = 2.7$ ,  $p$   
45  $< 0.001$ ), and in β<sub>2</sub>-AR deficient mice (Figure 4(d);  $F_{10,150} = 1.8$ ,  $p < 0.05$ ).  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

#### 56 *Effect of opioid receptor antagonists on long lasting formoterol treatment*

57  
58  
59  
60

1  
2  
3 To confirm the role of DOP receptors, independently from any developmental or lasting alteration of  
4 nociceptive pathway that may accompany opioid receptor deletion, we tested the consequence of an  
5 acute injection of the MOP receptor antagonist naloxonazine and the DOP receptor antagonist  
6 naltrindole (Figure 5). After 3 weeks of treatment with formoterol or saccharin, an acute injection of  
7 naltrindole temporarily suppressed the antiallodynic effect of formoterol treatment (Figure 5;  $F_{2,24} = 5.3$ ,  
8  $p < 0.005$ ); while naloxonazine had no effect on mechanical thresholds for paw withdrawal. We also  
9 observed that naltrindole had no effect *per se* in mice with Sham surgery or in mice that received  
10 saccharin alone.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

## Discussion

In the present work, we assessed the role of the opioid receptors in the antiallodynic effect of two  $\beta_2$ -mimetics, one with a short half-life, terbutaline, given intraperitoneally, and the other one with a long half-life, formoterol, given orally. We found that DOP receptors, but not MOP or KOP receptors, were required to the effect of those two  $\beta_2$ -mimetics on mechanical hypersensitivity in a murine model of neuropathic pain.

Regardless of their half-life, terbutaline and formoterol exerted their effect with a similar therapeutic delay of about 13 days, which is also similar to the therapeutic delay of treatments with antidepressant drugs in the same model.<sup>9-11</sup> Present data with oral formoterol and previous reports with sustained systemic injections of  $\beta$ -mimetics<sup>12, 13</sup> also suggest that the dose, once effective, has only a minor influence on this delay. The delay of action of these treatments in the context of neuropathic pain thus appears partly independent from the pharmacokinetic properties of the molecules and ways of administration, supporting the hypothesis that the delay may be more likely linked to the setting up of molecular and cellular neuroplasticity phenomena, as it has been described with antidepressant drugs in the context of depression.<sup>35-37</sup>

$\beta_2$ -mimetics remained effective in mice deficient for MOP or KOP receptors, but lost their efficacy in mice deficient for DOP receptors, which seemed the sole opioid receptors necessary to the antiallodynic effect of  $\beta_2$ -mimetics. This finding is further supported by pharmacological data. Indeed, the acute injection of the DOP receptor antagonist naltrindole led to a transitory relapse of mechanical allodynia in mice chronically treated with  $\beta_2$ -mimetics. These results suggest a mechanism similar to the one previously observed for antidepressant drugs, whose antiallodynic action has also been shown to be dependent upon DOP receptors.<sup>9, 16, 19</sup> In the cuff model it was also shown that sustained neuropathic pain condition was associated with a reduction of DOP receptor expression in small calcitonin gene-related peptide positive primary sensory neurons and in free nerve endings, that was not present in duloxetine<sup>19</sup> treated animals and that was partly corrected in formoterol<sup>38</sup> treated animals. In physiological conditions, DOP receptor agonists have little noticeable effect on nociception, as shown by pharmacological studies and data in DOP receptor deficient mice.<sup>39</sup> However, under neuropathic pain conditions, the administration of DOP receptor agonists has been shown to decrease mechanical and

1  
2  
3 thermal pain modalities.<sup>40-44</sup> It has thus been suggested that DOP agonists may be of interest for pain  
4 treatment. Unfortunately, agonists of the DOP receptors cannot be presently used as appropriate clinical  
5 treatments for neuropathic pain. Indeed, while DOP agonists would have a lower abuse potential and  
6 life-threatening risk than MOP receptor agonists,<sup>39, 45</sup> the molecules presently available have adverse  
7 effects,<sup>46</sup> in particular convulsions or sleep apnea, that prevent their clinical use.

13  $\beta_2$ -AR and DOP receptors are both necessary to the antiallodynic effect of antidepressant  
14 drugs<sup>10, 11, 16</sup> and of  $\beta_2$ -mimetics. Interestingly, the contribution of these two receptors to an  
15 antinociceptive action has also been reported following intraplantar administration of a  $\beta$ -AR agonist in  
16 inflammatory pain,<sup>47</sup> as well as in the antiallodynic action of a prolonged treatment with curcuma in a  
17 model of sciatic nerve constriction.<sup>48</sup> The mechanistic link between these two receptors is however still  
18 to be explored. Since acute administration of naloxone methiodide, an antagonist which does not pass  
19 the blood-brain barrier, suppressed the antiallodynic effect of chronic terbutaline treatment, the  
20 peripheral opioid system can thus be considered as critical. Again, this peripheral DOP receptor  
21 component has also been observed concerning the antiallodynic action of prolonged treatment with  
22 antidepressant drugs.<sup>9, 19</sup> DOP receptors are present on primary afferents<sup>47, 49, 50</sup> and expressed by several  
23 classes of dorsal root ganglia neurons.<sup>19, 51</sup> On the other hand, the  $\beta_2$ -ARs, whose mRNA levels may  
24 increase in the dorsal root ganglia following sciatic nerve transection<sup>52</sup> but not after sciatic nerve  
25 cuffing,<sup>8</sup> were proposed to be preferentially expressed by the glial satellite cells of dorsal root ganglia.<sup>8</sup>  
26 These non-neuronal cells are the peripheral analogues of astrocytes of the central nervous system and  
27 are known to express  $\beta_2$ -AR at their membrane in various species including humans.<sup>53, 54</sup> Even though,  
28 in transfected cell cultures, the existence of heteromeric complexes of DOP receptors and  $\beta_2$ -AR has  
29 been studied,<sup>55-57</sup> the above anatomical evidence suggests that both receptors would unlikely be co-  
30 expressed by the same cells in dorsal root ganglia. The immediate relapse after an acute administration  
31 of naltrindole rather suggests that the opioid component is likely located downstream of the adrenergic  
32 component. We may thus hypothesize that the recruitment of  $\beta_2$ -AR could lead to an activation of the  
33 cAMP/PKA pathway in satellite glial cells, which could lead to synthesis and release of opioid peptides  
34 like enkephalins that would then stimulate DOP receptors present on primary afferents.<sup>47, 50</sup> Alternately,  
35 it could also be hypothesized that DOP receptors are simply part of a permissive mechanism, in which  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 their presence would be essential to the normal functioning of pathways responsible for the antiallodynic  
4 effect, without being *per se* an element of the molecular therapeutic cascade itself. This hypothesis could  
5 be supported by the fact that DOP receptors were shown to be more particularly involved in mechanical  
6 nociceptive responses.<sup>58</sup>  
7  
8  
9  
10  
11  
12

### 13 **Conclusion**

14  
15 In summary, the present findings show that  $\beta_2$ -mimetics, either intraperitoneal or *per os*, can have an  
16 antiallodynic action in a rodent model of sciatic nerve compression, and that DOP receptors are essential  
17 to it. Our results also show that neither MOP nor KOP receptors are necessary to this action of  $\beta_2$ -  
18 mimetics. Our data are also supportive of a peripheral location of the opioid component of  $\beta_2$ -mimetic  
19 effect. Together, these findings show a mechanistic convergence between  $\beta_2$ -mimetics the known  
20 antidepressant drugs' action in neuropathic pain models. These findings also support the need of future  
21 research to elucidate the mechanistic link between  $\beta_2$ -ARs and DOP receptors.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### **Author's Contributions**

M.K., S.M. and I.Y. did all surgeries. S.M. and Y.B. did all experiments concerning terbutaline effect. For formoterol experiments, M.K., X.W., L.N and R.A.H. performed dose-responses. M.K, L.N. and X.W. performed behavioral tests on chronically treated opioid-receptor deficient mice. M.K. performed behavioral tests concerning naloxonazine and naltrindole. S.D. genotyped the transgenic animals. M.B., M.K. D.M, I.Y. and E.S. codesigned and supervised all experiments. M.K. collected and analyzed all data. M.K. and M.B. drafted the article.

### **Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors declare that they have no competing interests.

### **Funding**

This work was supported by the Centre National de la Recherche Scientifique [contracts UPR3212 and UMR5293], the University of Strasbourg and the Agence Nationale de la Recherche [Euridol ANR-17-EURE-0022]; MK was supported by a CNRS disability doctoral fellowship, the Fondation d'Entreprise Banque Populaire and the Fédéh Hewlett Packard. We are grateful to Profs. Brigitte Kieffer and Claire Gavériaux-Ruff (Strasbourg, France) for providing MOP, DOP and KOP related mouse breeders.

## References

1. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS and Nurmikko T. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. *Eur J Neurol* 2010; 17: 1113-e1188. 2010/04/21. DOI: ENE2999 [pii]10.1111/j.1468-1331.2010.02999.x.
2. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, Kent JL, Krane EJ, Lebel AA, Levy RM, Mackey SC, Mayer J, Miaskowski C, Raja SN, Rice AS, Schmader KE, Stacey B, Stanos S, Treede RD, Turk DC, Walco GA and Wells CD. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. *Mayo Clin Proc* 2010; 85: S3-14. DOI: 10.4065/mcp.2009.0649.
3. Saarto T and Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. *J Neurol Neurosurg Psychiatry* 2010; 81: 1372-1373. DOI: 10.1136/jnnp.2008.144964.
4. Kremer M, Salvat E, Muller A, Yalcin I and Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. *Neuroscience* 2016; 338: 183-206. DOI: 10.1016/j.neuroscience.2016.06.057.
5. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B and Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. *N Engl J Med* 1992; 326: 1250-1256. 1992/05/07. DOI: 10.1056/NEJM199205073261904.
6. Benbouzid M, Choucair-Jaafar N, Yalcin I, Waltisperger E, Muller A, Freund-Mercier MJ and Barrot M. Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice. *Eur J Pain* 2008; 12: 1008-1017. 2008/03/12. DOI: S1090-3801(08)00018-9 [pii]10.1016/j.ejpain.2008.01.010.
7. Benbouzid M, Pallage V, Rajalu M, Waltisperger E, Doridot S, Poisbeau P, Freund-Mercier MJ and Barrot M. Sciatic nerve cuffing in mice: a model of sustained neuropathic pain. *Eur J Pain* 2008; 12: 591-599. 2007/11/17. DOI: S1090-3801(07)00654-4 [pii]10.1016/j.ejpain.2007.10.002.
8. Bohren Y, Tessier LH, Megat S, Petitjean H, Hugel S, Daniel D, Kremer M, Fournel S, Hein L, Schlichter R, Freund-Mercier MJ, Yalcin I and Barrot M. Antidepressants suppress neuropathic pain by a peripheral beta2-adrenoceptor mediated anti-TNFalpha mechanism. *Neurobiol Dis* 2013; 60: 39-50. 2013/08/28. DOI: S0969-9961(13)00233-7 [pii]10.1016/j.nbd.2013.08.012.
9. Kremer M, Yalcin I, Goumon Y, Wurtz X, Nexon L, Daniel D, Megat S, Ceredig RA, Ernst C, Turecki G, Chavant V, Theroux JF, Lacaud A, Joganah LE, Lelievre V, Massotte D, Lutz PE, Gilsbach R, Salvat E and Barrot M. A Dual Noradrenergic Mechanism for the Relief of Neuropathic Allodynia by the Antidepressant Drugs Duloxetine and Amitriptyline. *J Neurosci* 2018; 38: 9934-9954. DOI: 10.1523/JNEUROSCI.1004-18.2018.
10. Yalcin I, Tessier LH, Petit-Demouliere N, Doridot S, Hein L, Freund-Mercier MJ and Barrot M. Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. *Neurobiol Dis* 2009; 33: 386-394. 2008/12/17. DOI: S0969-9961(08)00281-7 [pii] 10.1016/j.nbd.2008.11.003.
11. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ and Barrot M. beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. *Ann Neurol* 2009; 65: 218-225. 2009/03/05. DOI: 10.1002/ana.21542.
12. Yalcin I, Tessier LH, Petit-Demouliere N, Waltisperger E, Hein L, Freund-Mercier MJ and Barrot M. Chronic treatment with agonists of beta(2)-adrenergic receptors in neuropathic pain. *Exp Neurol* 2010; 221: 115-121. 2009/10/21. DOI: S0014-4886(09)00425-7 [pii] 10.1016/j.expneurol.2009.10.008.
13. Choucair-Jaafar N, Yalcin I, Rodeau JL, Waltisperger E, Freund-Mercier MJ and Barrot M. Beta2-adrenoceptor agonists alleviate neuropathic allodynia in mice after chronic treatment. *Br J Pharmacol* 2009; 158: 1683-1694. DOI: 10.1111/j.1476-5381.2009.00510.x.
14. Cok OY, Eker HE, Yalcin I, Barrot M and Aribogon A. Is there a place for beta-mimetics in clinical management of neuropathic pain? Salbutamol therapy in six cases. *Anesthesiology* 2010; 112: 1276-1279. DOI: 10.1097/ALN.0b013e3181d40399.
15. Salvat E, Schweitzer B, Massard G, Meyer N, de Blay F, Muller A and Barrot M. Effects of beta2 agonists on post-thoracotomy pain incidence. *Eur J Pain* 2015; 19: 1428-1436. DOI: 10.1002/ejp.673.

16. Benbouzid M, Gaveriaux-Ruff C, Yalcin I, Waltisperger E, Tessier LH, Muller A, Kieffer BL, Freund-Mercier MJ and Barrot M. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. *Biol Psychiatry* 2008; 63: 633-636. 2007/08/19. DOI: S0006-3223(07)00591-4 [pii] 10.1016/j.biopsych.2007.06.016.
17. Bohren Y, Karavelic D, Tessier LH, Yalcin I, Gaveriaux-Ruff C, Kieffer BL, Freund-Mercier MJ and Barrot M. Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia. *Eur J Pain* 2010; 14: 700-704. 2010/01/09. DOI: S1090-3801(09)00249-3 [pii] 10.1016/j.ejpain.2009.11.014.
18. Megat S, Bohren Y, Doridot S, Gaveriaux-Ruff C, Kieffer BL, Freund-Mercier MJ, Yalcin I and Barrot M. kappa-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain. *Br J Pharmacol* 2015; 172: 1034-1044. 2014/10/10. DOI: 10.1111/bph.12963.
19. Ceredig RA, Pierre F, Doridot S, Alduntzin U, Salvat E, Yalcin I, Gaveriaux-Ruff C, Barrot M and Massotte D. Peripheral delta opioid receptors mediate duloxetine antiallodynic effect in a mouse model of neuropathic pain. *Eur J Neurosci* 2018; 48: 2231-2246. DOI: 10.1111/ejn.14093.
20. Mogil JS, Yu L and Basbaum AI. Pain genes?: natural variation and transgenic mutants. *Annu Rev Neurosci* 2000; 23: 777-811. 2000/06/09. DOI: 10.1146/annurev.neuro.23.1.777.
21. Gaveriaux-Ruff C and Kieffer BL. Opioid receptor genes inactivated in mice: the highlights. *Neuropeptides* 2002; 36: 62-71. 2002/10/03. DOI: S0143417902909005 [pii].
22. Marchand F, Alloui A, Chapuy E, Jourdan D, Pelissier T, Ardid D, Hernandez A and Eschalier A. Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats. *Pain* 2003; 103: 229-235. 2003/06/07. DOI: S0304395903001684 [pii].
23. Mico JA, Ardid D, Berrocoso E and Eschalier A. Antidepressants and pain. *Trends Pharmacol Sci* 2006; 27: 348-354. 2006/06/10. DOI: S0165-6147(06)00129-5 [pii] 10.1016/j.tips.2006.05.004.
24. Choucair-Jaafar N, Salvat E, Freund-Mercier MJ and Barrot M. The antiallodynic action of nortriptyline and terbutaline is mediated by beta(2) adrenoceptors and delta opioid receptors in the ob/ob model of diabetic polyneuropathy. *Brain Res* 2014; 1546: 18-26. 2013/12/24. DOI: S0006-8993(13)01563-1 [pii] 10.1016/j.brainres.2013.12.016.
25. Cazzola M, Page CP, Rogliani P and Matera MG. beta2-agonist therapy in lung disease. *Am J Respir Crit Care Med* 2013; 187: 690-696. DOI: 10.1164/rccm.201209-1739PP.
26. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R and Kieffer BL. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. *Nat Genet* 2000; 25: 195-200. DOI: 10.1038/76061.
27. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP and Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* 1996; 383: 819-823. DOI: 10.1038/383819a0.
28. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R and Kieffer BL. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. *EMBO J* 1998; 17: 886-897. DOI: 10.1093/emboj/17.4.886.
29. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D and Kobilka BK. Targeted disruption of the beta2 adrenergic receptor gene. *J Biol Chem* 1999; 274: 16694-16700. DOI: 10.1074/jbc.274.24.16694.
30. Yalcin I, Megat S, Barthas F, Waltisperger E, Kremer M, Salvat E and Barrot M. The sciatic nerve cuffing model of neuropathic pain in mice. *J Vis Exp* 2014; 89: 51608. 2014/08/01. DOI: 10.3791/51608.
31. Barrot M. Tests and models of nociception and pain in rodents. *Neuroscience* 2012; 211: 39-50. DOI: 10.1016/j.neuroscience.2011.12.041.
32. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P and Simonnet G. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. *Anesthesiology* 2000; 92: 465-472. DOI: 10.1097/00000542-200002000-00029.

- 1  
2  
3 33. Nadal X, Banos JE, Kieffer BL and Maldonado R. Neuropathic pain is enhanced in delta-  
4 opioid receptor knockout mice. *Eur J Neurosci* 2006; 23: 830-834. DOI: 10.1111/j.1460-  
5 9568.2006.04569.x.
- 6 34. Kremer M, Yalcin I, Nexon L, Wurtz X, Ceredig RA, Daniel D, Hawkes RA, Salvat E and  
7 Barrot M. The antiallodynic action of pregabalin in neuropathic pain is independent from the opioid  
8 system. *Mol Pain* 2016; 12: 1744806916636387.
- 9 35. Duman RS. Pathophysiology of depression: the concept of synaptic plasticity. *Eur Psychiatry*  
10 2002; 17 Suppl 3: 306-310. 2004/06/05. DOI: S0924933802006545 [pii].
- 11 36. Vialou V, Feng J, Robison AJ and Nestler EJ. Epigenetic mechanisms of depression and  
12 antidepressant action. *Annu Rev Pharmacol Toxicol* 2013; 53: 59-87. 2012/10/02. DOI:  
13 10.1146/annurev-pharmtox-010611-134540.
- 14 37. Rantamaki T and Yalcin I. Antidepressant drug action--From rapid changes on network  
15 function to network rewiring. *Prog Neuropsychopharmacol Biol Psychiatry* 2016; 64: 285-292.  
16 2015/06/13. DOI: S0278-5846(15)00128-1 [pii] 10.1016/j.pnpbp.2015.06.001.
- 17 38. Ceredig RA, Pierre F, Doridot S, Alduntzin U, Salvat E, Yalcin I, Gaveriaux-Ruff C, Barrot M  
18 and Massotte D. Peripheral Delta Opioid Receptors Mediate Formoterol Anti-allodynic Effect in a  
19 Mouse Model of Neuropathic Pain. *Frontiers in Molecular Neuroscience* 2020; 12: 324.
- 20 39. Gaveriaux-Ruff C and Kieffer BL. Delta opioid receptor analgesia: recent contributions from  
21 pharmacology and molecular approaches. *Behav Pharmacol* 2011; 22: 405-414. DOI:  
22 10.1097/FBP.0b013e32834a1f2c.
- 23 40. Kabli N and Cahill CM. Anti-allodynic effects of peripheral delta opioid receptors in  
24 neuropathic pain. *Pain* 2007; 127: 84-93. DOI: 10.1016/j.pain.2006.08.003.
- 25 41. Hervera A, Negrete R, Leanez S, Martin-Campos J and Pol O. The role of nitric oxide in the  
26 local antiallodynic and antihyperalgesic effects and expression of delta-opioid and cannabinoid-2  
27 receptors during neuropathic pain in mice. *J Pharmacol Exp Ther* 2010; 334: 887-896. DOI:  
28 10.1124/jpet.110.167585.
- 29 42. Mika J, Przewlocki R and Przewlocka B. The role of delta-opioid receptor subtypes in  
30 neuropathic pain. *Eur J Pharmacol* 2001; 415: 31-37. DOI: 10.1016/s0014-2999(01)00814-7.
- 31 43. Saitoh A and Nagase H. Delta Opioid Receptor (DOR) Ligands and Pharmacology:  
32 Development of Indolo- and Quinolinomorphinan Derivatives Based on the Message-Address  
33 Concept. *Handb Exp Pharmacol* 2018; 247: 3-19. DOI: 10.1007/164\_2016\_18.
- 34 44. Castany S, Carcole M, Leanez S and Pol O. The antinociceptive effects of a delta-opioid  
35 receptor agonist in mice with painful diabetic neuropathy: Involvement of heme oxygenase 1.  
36 *Neurosci Lett* 2016; 614: 49-54. DOI: 10.1016/j.neulet.2015.12.059.
- 37 45. Gallantine EL and Meert TF. A comparison of the antinociceptive and adverse effects of the  
38 mu-opioid agonist morphine and the delta-opioid agonist SNC80. *Basic Clin Pharmacol Toxicol* 2005;  
39 97: 39-51. DOI: 10.1111/j.1742-7843.2005.pto\_97107.x.
- 40 46. Peppin JF and Raffa RB. Delta opioid agonists: a concise update on potential therapeutic  
41 applications. *J Clin Pharm Ther* 2015; 40: 155-166. DOI: 10.1111/jcpt.12244.
- 42 47. Binder W, Mousa SA, Sitte N, Kaiser M, Stein C and Schafer M. Sympathetic activation  
43 triggers endogenous opioid release and analgesia within peripheral inflamed tissue. *Eur J Neurosci*  
44 2004; 20: 92-100. 2004/07/13. DOI: 10.1111/j.1460-9568.2004.03459.x EJM3459 [pii].
- 45 48. Zhao X, Xu Y, Zhao Q, Chen CR, Liu AM and Huang ZL. Curcumin exerts antinociceptive  
46 effects in a mouse model of neuropathic pain: descending monoamine system and opioid receptors are  
47 differentially involved. *Neuropharmacology* 2012; 62: 843-854. DOI:  
48 10.1016/j.neuropharm.2011.08.050.
- 49 49. Mennicken F, Zhang J, Hoffert C, Ahmad S, Beaudet A and O'Donnell D. Phylogenetic  
50 changes in the expression of delta opioid receptors in spinal cord and dorsal root ganglia. *J Comp  
51 Neurol* 2003; 465: 349-360. DOI: 10.1002/cne.10839.
- 52 50. Busch-Dienstfertig M and Stein C. Opioid receptors and opioid peptide-producing leukocytes  
53 in inflammatory pain--basic and therapeutic aspects. *Brain Behav Immun* 2010; 24: 683-694. DOI:  
54 10.1016/j.bbi.2009.10.013.
- 55 51. Francois A, Low SA, Sypek EI, Christensen AJ, Sotoudeh C, Beier KT, Ramakrishnan C,  
56 Ritola KD, Sharif-Naeini R, Deisseroth K, Delp SL, Malenka RC, Luo L, Hantman AW and Scherrer  
57  
58  
59  
60

- 1  
2  
3 G. A Brainstem-Spinal Cord Inhibitory Circuit for Mechanical Pain Modulation by GABA and  
4 Enkephalins. *Neuron* 2017; 93: 822-839 e826. DOI: 10.1016/j.neuron.2017.01.008.
- 5 52. Maruo K, Yamamoto H, Yamamoto S, Nagata T, Fujikawa H, Kanno T, Yaguchi T, Maruo S,  
6 Yoshiya S and Nishizaki T. Modulation of P2X receptors via adrenergic pathways in rat dorsal root  
7 ganglion neurons after sciatic nerve injury. *Pain* 2006; 120: 106-112. DOI:  
8 10.1016/j.pain.2005.10.016.
- 9 53. Trimmer PA, Evans T, Smith MM, Harden TK and McCarthy KD. Combination of  
10 immunocytochemistry and radioligand receptor assay to identify beta-adrenergic receptor subtypes on  
11 astroglia in vitro. *J Neurosci* 1984; 4: 1598-1606.
- 12 54. Mantyh PW, Rogers SD, Allen CJ, Catton MD, Ghilardi JR, Levin LA, Maggio JE and Vigna  
13 SR. Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous  
14 system in the rat, rabbit, and human. *J Neurosci* 1995; 15: 152-164.
- 15 55. Cao TT, Brelot A and von Zastrow M. The composition of the beta-2 adrenergic receptor  
16 oligomer affects its membrane trafficking after ligand-induced endocytosis. *Mol Pharmacol* 2005; 67:  
17 288-297. DOI: 10.1124/mol.104.003608.
- 18 56. Jordan BA, Trapaidze N, Gomes I, Nivarthi R and Devi LA. Oligomerization of opioid  
19 receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase  
20 activation. *Proc Natl Acad Sci U S A* 2001; 98: 343-348. 2001/01/03. DOI: 10.1073/pnas.011384898  
21 011384898 [pii].
- 22 57. Ramsay D, Kellett E, McVey M, Rees S and Milligan G. Homo- and hetero-oligomeric  
23 interactions between G-protein-coupled receptors in living cells monitored by two variants of  
24 bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form  
25 more efficiently than between less closely related sequences. *Biochem J* 2002; 365: 429-440. DOI:  
26 10.1042/BJ20020251.
- 27 58. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL and  
28 Basbaum AI. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain.  
29 *Cell* 2009; 137: 1148-1159. DOI: 10.1016/j.cell.2009.04.019.
- 30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Legends

### Figure 1. DOP receptors, but not MOP or KOP receptors, are critical to terbutaline treatment of mechanical allodynia

Two weeks after unilateral surgery on the right hindpaw, terbutaline treatment (0.5 mg/kg, i.p., twice a day) or its saline control solution started and continued until day 36 post-surgery. The mechanical threshold of hindpaw withdrawal was evaluated using von Frey filaments. **(a)** Chronic terbutaline treatment reversed the mechanical hypersensitivity in wild-type mice ( $n = 8-9$  per group,  $*p < 0.01$  compared to Sham-operated controls receiving Saline). **(b)** Wild-type, MOP<sup>-/-</sup>, DOP<sup>-/-</sup> and KOP<sup>-/-</sup> mice displayed the same baseline for mechanical sensitivity and the same cuff-induced mechanical hypersensitivity ( $n = 6-9$  per group,  $*p < 0.001$  for post-operative day 0 (baseline) compared to others post-operative days in each group). **(c)** Area under the curve (AUC) from post-surgical day 15 (first day of treatment) until the end of treatment, for wild-type, MOP<sup>-/-</sup>, DOP<sup>-/-</sup> and KOP<sup>-/-</sup> mice. The chronic terbutaline treatment suppressed the ipsilateral cuff-induced allodynia in MOP and KOP receptor-deficient mice but remained ineffective in DOP receptor-deficient mice ( $n = 8-12$  per group,  $*p < 0.01$  compared to WT mice receiving Saline). Data are expressed as mean  $\pm$  SEM, individual values are also displayed for the AUC.

### Figure 2. Pharmacological blockade of DOP receptors induced a relapse of allodynia in terbutaline-treated mice

After 3 weeks of chronic terbutaline treatment (0.5 mg/kg, i.p., twice a day), mice received an acute injection of opioid receptor antagonists. **(a)** The acute administration of naltrindole (5 mg/kg, s.c.), a DOP receptor antagonist, suppressed the antiallodynic effect of terbutaline in wild-type, MOP<sup>-/-</sup> and KOP<sup>-/-</sup> mice. **(b)** The acute administration of naloxone methiodide (5 mg/kg, s.c.), an opioid receptor antagonist that does not cross the blood-brain barrier, induced a relapse of allodynia in terbutaline treated mice. Mice were tested before (0) and 30 min after the acute injection. ( $n = 8-12$  per group,  $*p < 0.05$  compared to Sham-operated controls chronically treated with saline). Data are expressed as mean  $\pm$  SEM.

**Figure 3. Chronic oral formoterol treatment suppresses cuff-induced mechanical allodynia**

Nineteen days after unilateral surgery on the right hindpaw, the chronic oral treatment with formoterol started and lasted 21 days. **(a)** The animals ( $n = 5$  per group) received formoterol (0.001, 0.05, 0.1 or 0.5  $\mu\text{g}/\text{mL}$ ) with saccharin 0.02% or saccharin alone in the drinking water as the sole source of fluid. The mechanical sensitivity (paw withdrawal thresholds, PWT) was evaluated over days using von Frey filaments. Control treatment (Saccharin 0.02%) did not affect the mechanical sensitivity. Chronic oral formoterol treatment at the three highest doses reversed the cuff-induced allodynia. The treatment at dose 0.001  $\mu\text{g}/\text{mL}$  had no effect. **(b)** Area under the curve (AUC) from for post-surgical day 19 (first day of treatment) until the end of the treatment for formoterol (0.001, 0.05, 0.1 or 0.5  $\mu\text{g}/\text{mL}$ ).  $*p < 0.05$  compared to Cuff-operated control group drinking vehicle. **(c)** Histogram showing the equivalence between  $\mu\text{g}/\text{mL}$  and  $\mu\text{g}/\text{kg}/\text{day}$  of the different doses. **(d)** Formoterol treatment (0.5  $\mu\text{g}/\text{mL}$ ) did not affect mechanical sensitivity of sham-operated mice. Data are expressed as mean  $\pm$  SEM, individual values are also displayed for AUC.

**Figure 4. DOP receptors, but not MOP or KOP receptors, are critical to formoterol treatment of mechanical allodynia**

Between 15 and 19 days post-surgery, the oral treatment with formoterol (0.5  $\mu\text{g}/\text{ml}$ ) or its saccharin 0.02% solution control started and was maintained for over 3 weeks. Mechanical allodynia was tested using von Frey filaments. **(a)** The mechanical sensitivity thresholds (PWT) of female mice is lower than that of male mice. However, both sexes developed mechanical allodynia similarly, and formoterol was effective in reversing the cuff-induced allodynia in both male and female mice. Males and females were then pooled in each experimental group, with an equal number of mice of both sexes in each group. **(b)**, **(c)** Chronic formoterol treatment suppressed the ipsilateral cuff-induced allodynia in wild-type mice, as well as in MOP and KOP receptor-deficient mice, but it remained ineffective in DOP receptor-deficient mice. **(d)** Formoterol had no action on mechanical allodynia in  $\beta_2$ -AR deficient mice. ( $n = 3$ -4 males and 3-4 females per group,  $*p < 0.05$  compared to Sham-operated control group drinking vehicle). Data are expressed as mean  $\pm$  SEM.

1  
2  
3 **Figure 5. Pharmacological blockade of DOP receptors induced a relapse of allodynia in**  
4 **formoterol-treated mice**  
5

6  
7 After at least 3 weeks of formoterol or saccharin treatment, mice received an injection of the MOP  
8 receptor antagonist naloxonazine (30 mg/kg, s.c.), DOP receptor antagonist naltrindole (5 mg/kg, s.c.),  
9 or their control saline solution. The mechanical threshold was measured before, 30 min and 1 h after  
10 acute injection. Naltrindole, but not naloxonazine, induced a transitory relapse of mechanical allodynia  
11 in neuropathic mice treated by formoterol. Data are expressed as mean  $\pm$  SEM (n = 5 per group, \* $p$  <  
12 0.001 compared to Sham-operated control group drinking vehicle).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review






Figure 1

162x62mm (300 x 300 DPI)




Figure 2

167x61mm (300 x 300 DPI)




Figure 3

156x131mm (300 x 300 DPI)




Figure 4

172x155mm (300 x 300 DPI)




Figure 5

146x51mm (300 x 300 DPI)

## Supplemental Material

Table 1. Detailed Statistical analysis.

Experiment	Assessment	Treatment	Test	Groups (n)	Analysis	Statistics	Post-hoc	Figure
Terbutaline treatment in WT mice	Mechanical PWT	NP surgery Chronic terbutaline	von Frey	Sham, Saline (8) Sham, Terbutaline (8) Cuff, Saline (9) Cuff, Terbutaline (9)	Group x Time Repeated measures ANOVA	$F_{7,231}=10.25$ , $p<0.001$	$p<0.001$ : D4 to D35: "Cuff Saline" < "Sham Saline"; D28 to D35: "Cuff Saline" < "Cuff, Terbutaline"	<b>1(a)</b>
Mechanical allodynia in WT, KOP <sup>-/-</sup> , MOP <sup>-/-</sup> , DOP <sup>-/-</sup> mice	Mechanical PWT	NP surgery Genotype	von Frey	Cuff, WT (9) Cuff, KOP <sup>-/-</sup> (6) Cuff, MOP <sup>-/-</sup> (7) Cuff, DOP <sup>-/-</sup> (6)	Group x Time Repeated measures ANOVA	$F_{18,432}=1.20$ , $p=0.16$	$p<0.001$ : D0 > D2 to D36 for all groups	<b>1(b)</b>
Terbutaline treatment in opioid receptor deficient mice	AUC	NP surgery Chronic terbutaline		WT, Cuff Saline (9) WT, Cuff Terbutaline (9) KOP <sup>-/-</sup> , Cuff Terbutaline (8) MOP <sup>-/-</sup> , Cuff Terbutaline (10) DOP <sup>-/-</sup> , Cuff Terbutaline (12)	Genotype x Treatment One-way ANOVA	$F_{3,23}=23.82$ , $p<0.001$	$p<0.01$ : ("WT, Cuff Saline" = DOP <sup>-/-</sup> , Cuff Terbutaline) < ("WT, Cuff Terbutaline" = KOP <sup>-/-</sup> , Cuff Terbutaline) = ("MOP <sup>-/-</sup> , Cuff Terbutaline")	<b>1(c)</b>
Effect of naltrindole on terbutaline treatment in WT mice	Mechanical PWT	NP surgery Chronic terbutaline + acute naltrindole	von Frey	Sham, Saline (8) Sham, Terbutaline (8) Cuff, Saline (9) Cuff, Terbutaline (9)	Group x Time Repeated measures ANOVA	$F_{1,33}=18.83$ , $p<0.001$	$p<0.01$ : T30 min: ("Cuff Terbutaline" = "Cuff Saline") < ("Sham Saline" = "Sham Terbutaline")	<b>2(a)</b>
Effect of naltrindole on terbutaline treatment in MOP <sup>-/-</sup> mice	Mechanical PWT	NP surgery Chronic terbutaline + acute naltrindole	von Frey	Sham, Saline (9) Sham, Terbutaline (8) Cuff, Saline (12) Cuff, Terbutaline (10)	Group x Time Repeated measures ANOVA	$F_{1,21}=21.61$ , $p<0.001$	$p<0.05$ : T30 min: ("Cuff Terbutaline" = "Cuff Saline") < ("Sham Saline" = "Sham Terbutaline")	<b>2(a)</b>
Effect of naltrindole on terbutaline treatment in KOP <sup>-/-</sup> mice	Mechanical PWT	NP surgery Chronic terbutaline + acute naltrindole	von Frey	Sham, Saline (9) Sham, Terbutaline (8) Cuff, Saline (9) Cuff, Terbutaline (8)	Group x Time Repeated measures ANOVA	$F_{1,20}=5.05$ , $p<0.01$	$p<0.01$ : T30 min: ("Cuff Terbutaline" = "Cuff Saline") < ("Sham Saline" = "Sham Terbutaline")	<b>2(a)</b>
Peripheral opioid receptors and	Mechanical PWT	NP surgery Chronic terbutaline +	von Frey	Sham, Saline (8) Cuff, Terbutaline (9)	Group x Time Repeated measures ANOVA	$F_{1,20}=10.90$ , $p<0.01$	$p<0.01$ : T30 min: "Cuff Terbutaline" < "Sham Saline"	<b>2(b)</b>



				Cuff, Formoterol 0.5 µg/mL (6)				
Chronic oral formoterol in KOP <sup>-/-</sup> mice	Mechanical PWT	NP surgery Chronic formoterol	von Frey	Sham, Saccharin (6) Cuff, Saccharin (6) Cuff, Formoterol 0.5 µg/mL (6)	Group x Time Repeated measures ANOVA	$F_{10,150}=4.1,$ $p<0.001$	$p<0.05$ : D15: "Cuff Saccharin" < "Cuff Formoterol"; $p<0.001$ : D22 to D26: "Cuff Saccharin" < "Cuff Formoterol"	<b>4(c)</b>
Chronic oral formoterol in $\beta_2$ -AR <sup>-/-</sup> mice	Mechanical PWT	NP surgery Chronic formoterol	von Frey	Sham, Saccharin (6) Cuff, Saccharin (6) Cuff, Formoterol 0.5 µg/mL (6)	Group x Time Repeated measures ANOVA	$F_{10,150}=1.8,$ $p>0.5$	$p<0.001$ : D0 to D26: "Cuff Formoterol" < "Sham Saccharin"	<b>4(c)</b>
Effect of opioid receptor antagonists on formoterol treatment (Saline control)	Mechanical PWT	NP surgery Chronic formoterol	von Frey	Sham, Saccharin (5) Cuff, Saccharin (5) Cuff, Formoterol 0.5 µg/mL (5)	Group x Time Repeated measures ANOVA	$F_{3,36}=0.5,$ $p>0.5$	$p<0.001$ : T0 to 60 min: "Cuff Formoterol" > "Cuff Saccharin"	<b>5</b>
Effect of naloxonazine on formoterol treatment	Mechanical PWT	NP surgery Chronic formoterol	von Frey	Sham, Saccharin (5) Cuff, Saccharin (5) Cuff, Formoterol 0.5 µg/mL (5)	Group x Time Repeated measures ANOVA	$F_{2,24}=0.7,$ $p>0.5$	$p<0.001$ : T0 to 60 min: "Cuff Formoterol" > "Cuff Saccharin"	<b>5</b>
Effect of naltrindole on formoterol treatment	Mechanical PWT	NP surgery Chronic formoterol	von Frey	Sham, Saccharin (5) Cuff, Saccharin (5) Cuff, Formoterol 0.5 µg/mL (5)	Group x Time Repeated measures ANOVA	$F_{2,24}=5.3,$ $p<0.005$	$p<0.001$ : T30min: "Cuff Formoterol" < "Sham Saccharin"	<b>5</b>

NP, neuropathic pain; PWT, paw withdrawal threshold